GDF15 expression was found to be elevated in tumours and in serum samples from patients suffering from and various cancer types, including pancreatic, colorectal and prostate cancer and melanoma and may cause resistance to chemotherapeutics 15,25–28. Here, GDF15 is linked to prostate carcinoma.